BERNSTEIN HAROLD (President, R&D & CMO) sold 15K shares of MAZE THERAPEUTICS, INC. on the open market
Open‑market sale worth $441.9K. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 4/2/2026ACC: 0002050172-26-000019
Officer· President, R&D & CMO
Since Mar 2026
-15K
Net shares
Net seller
$441.9K
Total sold
3
Open market trades
0B · 3S
5
Total transactions
15K acquired · 30K disposed
Non-Derivative Transactions4
Common Stock
Direct
Shares
+15K
Price / share
$10.42
Trade value
$156.30K
% of position
New position
4/1/2026
0.00→15K
Common Stock
Direct
Shares
−11.35K
Price / share
$29.24
Trade value
$331.95K
% of position
75.7%
4/1/2026
15K→3.65K
Common Stock
Direct
Shares
−3.35K
Price / share
$30.06
Trade value
$100.64K
% of position
91.8%
4/1/2026
3.65K→300.00
Common Stock
Direct
Shares
−300.00
Price / share
$31.07
Trade value
$9.32K
% of position
New position
4/1/2026
300.00→0.00
Total
Net shares
+0.00
Net value
-$285.60K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 4/1/2026 | M · Option Exercise | +15K | $10.42 | $156.30K | New position | 0.00 | 15K |
| Common Stock Direct | 4/1/2026 | S · Sale | −11.35K | $29.24 | $331.95K | 75.7% | 15K | 3.65K |
| Common Stock Direct | 4/1/2026 | S · Sale | −3.35K | $30.06 | $100.64K | 91.8% | 3.65K | 300.00 |
| Common Stock Direct | 4/1/2026 | S · Sale | −300.00 | $31.07 | $9.32K | New position | 300.00 | 0.00 |
| Total | +0.00 | -$285.60K | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
15K shares
Shares
−15K
Strike price
10.42
Held after
237.41K
Exercisable
—
4/1/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock15K shares | 4/1/2026 | M · Option Exercise | −15K | 10.42 | — | 237.41K |